Glymidine sodium
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide | |
| Clinical data | |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Bioavailability | High |
| Protein binding | 90% |
| Biological half-life | 3.8 hours |
| Identifiers | |
| CAS Number |
339-44-6 |
| ATC code | A10BC01 (WHO) |
| PubChem | CID 9565 |
| DrugBank |
DB01382 |
| ChemSpider |
9190 |
| UNII |
4C5I4BQZ8F |
| ChEMBL |
CHEMBL1697838 |
| Chemical data | |
| Formula | C13H15N3O4S |
| Molar mass | 309.34 g/mol |
| |
| |
| | |
Glymidine sodium (INN, also known as glycodiazine; trade name Gondafon) is a sulfonamide antidiabetic drug, structurally related to the sulfonylureas. It was first reported in 1964, and introduced to clinical use in Europe in the mid to late 1960s.[1]
References
- ↑ [No authors listed] (June 1967). "Glymidine". Br Med J 2 (5555): 817. doi:10.1136/bmj.2.5555.817. PMC 1843097. PMID 6029147.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
